Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery

This work was conducted in order to design, characterize, and evaluate stable liposomes containing the hydrophobic drug raloxifene HCl (RAL) and hydrophilic doxycycline HCl (DOX), two potentially synergistic agents for treating osteoporosis and other bone lesions, in conjunction with a radio frequen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AAPS PharmSciTech 2015-12, Vol.16 (6), p.1335-1343
Hauptverfasser: Malekar, Swapnil A., Sarode, Ashish L., Bach, Alvin C., Bose, Arijit, Bothun, Geoffrey, Worthen, David R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1343
container_issue 6
container_start_page 1335
container_title AAPS PharmSciTech
container_volume 16
creator Malekar, Swapnil A.
Sarode, Ashish L.
Bach, Alvin C.
Bose, Arijit
Bothun, Geoffrey
Worthen, David R.
description This work was conducted in order to design, characterize, and evaluate stable liposomes containing the hydrophobic drug raloxifene HCl (RAL) and hydrophilic doxycycline HCl (DOX), two potentially synergistic agents for treating osteoporosis and other bone lesions, in conjunction with a radio frequency-induced, hydrophobic magnetic nanoparticle-dependent triggering mechanism for drug release. Both drugs were successfully incorporated into liposomes by lipid film hydration, although combination drug loading compromised liposome stability. Liposome stability was improved by reducing the drug load and by including Pluronics® (PL) in the formulations. DOX did not appear to interact with the phospholipid membranes comprising the liposomes, and its release was maximized in the presence of radio frequency (RF) heating. In contrast, differential scanning calorimetry (DSC) and phosphorus-31 nuclear magnetic resonance ( 31 P-NMR) analysis revealed that RAL developed strong interactions with the phospholipid membranes, most notably with lipid phosphate head groups, resulting in significant changes in membrane thermodynamics. Likewise, RAL release from liposomes was minimal, even in the presence of RF heating. These studies may offer useful insights into the design and optimization of multidrug containing liposomes. The effects of RAL on liposome characteristics and drug release performance underscore the importance of appropriate physical-chemical analysis in order to identify and characterize drug-lipid interactions that may profoundly affect liposome properties and performance early in the formulation development process.
doi_str_mv 10.1208/s12249-015-0323-z
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4666254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1738822483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c545t-10346e439059b19af751dee05f9eb75eaca3b4c4a8d4b784d9f3130514df684b3</originalsourceid><addsrcrecordid>eNqNkU1LxDAQhoMofv8AL9Kjl2o-2-QiyK5fICqi55C20zXSJmvSLqy_3siq6EU8zcD7zsvMPAgdEHxMKJYnkVDKVY6JyDGjLH9bQ9tEMJwrxej6j34L7cT4gjFlRLFNtEWFVKpUahvdP5jG-uwiwOsIrl7mZ_VgF2aAJrs1znd27qPvIWatD9nEuyH4rkvixPeVdWaw3mXTMM6yKXR2AWG5hzZa00XY_6y76Oni_HFyld_cXV5Pzm7yWnAx5AQzXgBnCgtVEWXaUpAGAItWQVUKMLVhFa-5kQ2vSskb1TLCsCC8aQvJK7aLTle587HqoakhrWY6PQ-2N2GpvbH6t-Lss575heZFUVDBU8DRZ0Dw6fY46N7GGrrOOPBj1KSUpZJCcfUPK5MyoZAsWcnKWgcfY4D2eyOC9Qc0vYKmEzT9AU2_pZnDn6d8T3xRSga6MsQkuRkE_eLH4NJ7_0h9B5xkpFs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1738822483</pqid></control><display><type>article</type><title>Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>SpringerLink Journals - AutoHoldings</source><creator>Malekar, Swapnil A. ; Sarode, Ashish L. ; Bach, Alvin C. ; Bose, Arijit ; Bothun, Geoffrey ; Worthen, David R.</creator><creatorcontrib>Malekar, Swapnil A. ; Sarode, Ashish L. ; Bach, Alvin C. ; Bose, Arijit ; Bothun, Geoffrey ; Worthen, David R.</creatorcontrib><description>This work was conducted in order to design, characterize, and evaluate stable liposomes containing the hydrophobic drug raloxifene HCl (RAL) and hydrophilic doxycycline HCl (DOX), two potentially synergistic agents for treating osteoporosis and other bone lesions, in conjunction with a radio frequency-induced, hydrophobic magnetic nanoparticle-dependent triggering mechanism for drug release. Both drugs were successfully incorporated into liposomes by lipid film hydration, although combination drug loading compromised liposome stability. Liposome stability was improved by reducing the drug load and by including Pluronics® (PL) in the formulations. DOX did not appear to interact with the phospholipid membranes comprising the liposomes, and its release was maximized in the presence of radio frequency (RF) heating. In contrast, differential scanning calorimetry (DSC) and phosphorus-31 nuclear magnetic resonance ( 31 P-NMR) analysis revealed that RAL developed strong interactions with the phospholipid membranes, most notably with lipid phosphate head groups, resulting in significant changes in membrane thermodynamics. Likewise, RAL release from liposomes was minimal, even in the presence of RF heating. These studies may offer useful insights into the design and optimization of multidrug containing liposomes. The effects of RAL on liposome characteristics and drug release performance underscore the importance of appropriate physical-chemical analysis in order to identify and characterize drug-lipid interactions that may profoundly affect liposome properties and performance early in the formulation development process.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-015-0323-z</identifier><identifier>PMID: 25899799</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Chemistry, Pharmaceutical - methods ; Delayed-Action Preparations - chemistry ; Doxorubicin - chemistry ; Drug Combinations ; Drug Delivery Systems - methods ; Drug Stability ; Hydrophobic and Hydrophilic Interactions ; Liposomes - chemistry ; Nanoparticles - chemistry ; Pharmacology/Toxicology ; Pharmacy ; Phospholipids - chemistry ; Poloxamer - chemistry ; Research Article</subject><ispartof>AAPS PharmSciTech, 2015-12, Vol.16 (6), p.1335-1343</ispartof><rights>American Association of Pharmaceutical Scientists 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c545t-10346e439059b19af751dee05f9eb75eaca3b4c4a8d4b784d9f3130514df684b3</citedby><cites>FETCH-LOGICAL-c545t-10346e439059b19af751dee05f9eb75eaca3b4c4a8d4b784d9f3130514df684b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666254/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666254/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25899799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malekar, Swapnil A.</creatorcontrib><creatorcontrib>Sarode, Ashish L.</creatorcontrib><creatorcontrib>Bach, Alvin C.</creatorcontrib><creatorcontrib>Bose, Arijit</creatorcontrib><creatorcontrib>Bothun, Geoffrey</creatorcontrib><creatorcontrib>Worthen, David R.</creatorcontrib><title>Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>This work was conducted in order to design, characterize, and evaluate stable liposomes containing the hydrophobic drug raloxifene HCl (RAL) and hydrophilic doxycycline HCl (DOX), two potentially synergistic agents for treating osteoporosis and other bone lesions, in conjunction with a radio frequency-induced, hydrophobic magnetic nanoparticle-dependent triggering mechanism for drug release. Both drugs were successfully incorporated into liposomes by lipid film hydration, although combination drug loading compromised liposome stability. Liposome stability was improved by reducing the drug load and by including Pluronics® (PL) in the formulations. DOX did not appear to interact with the phospholipid membranes comprising the liposomes, and its release was maximized in the presence of radio frequency (RF) heating. In contrast, differential scanning calorimetry (DSC) and phosphorus-31 nuclear magnetic resonance ( 31 P-NMR) analysis revealed that RAL developed strong interactions with the phospholipid membranes, most notably with lipid phosphate head groups, resulting in significant changes in membrane thermodynamics. Likewise, RAL release from liposomes was minimal, even in the presence of RF heating. These studies may offer useful insights into the design and optimization of multidrug containing liposomes. The effects of RAL on liposome characteristics and drug release performance underscore the importance of appropriate physical-chemical analysis in order to identify and characterize drug-lipid interactions that may profoundly affect liposome properties and performance early in the formulation development process.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Delayed-Action Preparations - chemistry</subject><subject>Doxorubicin - chemistry</subject><subject>Drug Combinations</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Stability</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Liposomes - chemistry</subject><subject>Nanoparticles - chemistry</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Phospholipids - chemistry</subject><subject>Poloxamer - chemistry</subject><subject>Research Article</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1LxDAQhoMofv8AL9Kjl2o-2-QiyK5fICqi55C20zXSJmvSLqy_3siq6EU8zcD7zsvMPAgdEHxMKJYnkVDKVY6JyDGjLH9bQ9tEMJwrxej6j34L7cT4gjFlRLFNtEWFVKpUahvdP5jG-uwiwOsIrl7mZ_VgF2aAJrs1znd27qPvIWatD9nEuyH4rkvixPeVdWaw3mXTMM6yKXR2AWG5hzZa00XY_6y76Oni_HFyld_cXV5Pzm7yWnAx5AQzXgBnCgtVEWXaUpAGAItWQVUKMLVhFa-5kQ2vSskb1TLCsCC8aQvJK7aLTle587HqoakhrWY6PQ-2N2GpvbH6t-Lss575heZFUVDBU8DRZ0Dw6fY46N7GGrrOOPBj1KSUpZJCcfUPK5MyoZAsWcnKWgcfY4D2eyOC9Qc0vYKmEzT9AU2_pZnDn6d8T3xRSga6MsQkuRkE_eLH4NJ7_0h9B5xkpFs</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Malekar, Swapnil A.</creator><creator>Sarode, Ashish L.</creator><creator>Bach, Alvin C.</creator><creator>Bose, Arijit</creator><creator>Bothun, Geoffrey</creator><creator>Worthen, David R.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20151201</creationdate><title>Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery</title><author>Malekar, Swapnil A. ; Sarode, Ashish L. ; Bach, Alvin C. ; Bose, Arijit ; Bothun, Geoffrey ; Worthen, David R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c545t-10346e439059b19af751dee05f9eb75eaca3b4c4a8d4b784d9f3130514df684b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Delayed-Action Preparations - chemistry</topic><topic>Doxorubicin - chemistry</topic><topic>Drug Combinations</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Stability</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Liposomes - chemistry</topic><topic>Nanoparticles - chemistry</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Phospholipids - chemistry</topic><topic>Poloxamer - chemistry</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malekar, Swapnil A.</creatorcontrib><creatorcontrib>Sarode, Ashish L.</creatorcontrib><creatorcontrib>Bach, Alvin C.</creatorcontrib><creatorcontrib>Bose, Arijit</creatorcontrib><creatorcontrib>Bothun, Geoffrey</creatorcontrib><creatorcontrib>Worthen, David R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malekar, Swapnil A.</au><au>Sarode, Ashish L.</au><au>Bach, Alvin C.</au><au>Bose, Arijit</au><au>Bothun, Geoffrey</au><au>Worthen, David R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>16</volume><issue>6</issue><spage>1335</spage><epage>1343</epage><pages>1335-1343</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>This work was conducted in order to design, characterize, and evaluate stable liposomes containing the hydrophobic drug raloxifene HCl (RAL) and hydrophilic doxycycline HCl (DOX), two potentially synergistic agents for treating osteoporosis and other bone lesions, in conjunction with a radio frequency-induced, hydrophobic magnetic nanoparticle-dependent triggering mechanism for drug release. Both drugs were successfully incorporated into liposomes by lipid film hydration, although combination drug loading compromised liposome stability. Liposome stability was improved by reducing the drug load and by including Pluronics® (PL) in the formulations. DOX did not appear to interact with the phospholipid membranes comprising the liposomes, and its release was maximized in the presence of radio frequency (RF) heating. In contrast, differential scanning calorimetry (DSC) and phosphorus-31 nuclear magnetic resonance ( 31 P-NMR) analysis revealed that RAL developed strong interactions with the phospholipid membranes, most notably with lipid phosphate head groups, resulting in significant changes in membrane thermodynamics. Likewise, RAL release from liposomes was minimal, even in the presence of RF heating. These studies may offer useful insights into the design and optimization of multidrug containing liposomes. The effects of RAL on liposome characteristics and drug release performance underscore the importance of appropriate physical-chemical analysis in order to identify and characterize drug-lipid interactions that may profoundly affect liposome properties and performance early in the formulation development process.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25899799</pmid><doi>10.1208/s12249-015-0323-z</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1530-9932
ispartof AAPS PharmSciTech, 2015-12, Vol.16 (6), p.1335-1343
issn 1530-9932
1530-9932
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4666254
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; SpringerLink Journals - AutoHoldings
subjects Biochemistry
Biomedical and Life Sciences
Biomedicine
Biotechnology
Chemistry, Pharmaceutical - methods
Delayed-Action Preparations - chemistry
Doxorubicin - chemistry
Drug Combinations
Drug Delivery Systems - methods
Drug Stability
Hydrophobic and Hydrophilic Interactions
Liposomes - chemistry
Nanoparticles - chemistry
Pharmacology/Toxicology
Pharmacy
Phospholipids - chemistry
Poloxamer - chemistry
Research Article
title Radio Frequency-Activated Nanoliposomes for Controlled Combination Drug Delivery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A16%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radio%20Frequency-Activated%20Nanoliposomes%20for%20Controlled%20Combination%20Drug%20Delivery&rft.jtitle=AAPS%20PharmSciTech&rft.au=Malekar,%20Swapnil%20A.&rft.date=2015-12-01&rft.volume=16&rft.issue=6&rft.spage=1335&rft.epage=1343&rft.pages=1335-1343&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-015-0323-z&rft_dat=%3Cproquest_pubme%3E1738822483%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1738822483&rft_id=info:pmid/25899799&rfr_iscdi=true